คำอธิบาย
Aripiprazole acts as a partial D2 agonist/antagonist and can oppose levodopa's dopaminergic therapy, worsening Parkinson's disease symptoms.
กลไก
Aripiprazole's partial D2 agonism results in net D2 receptor blockade in the context of high dopamine from levodopa therapy, impairing motor function.
ความสำคัญทางคลินิก
Parkinson's patients treated with dopaminergic therapy can experience marked motor deterioration when any D2-acting antipsychotic is initiated.
การจัดการ
Avoid aripiprazole in Parkinson's disease; use medications with minimal D2 blockade for psychosis treatment in these patients.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.